Latest & greatest articles for thyroid

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on thyroid or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on thyroid and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for thyroid

61. The impact of levothyroxine in women with positive thyroid antibodies on pregnancy and obstetrical outcomes a systematic review and meta-analysis of randomized controlled trials

The impact of levothyroxine in women with positive thyroid antibodies on pregnancy and obstetrical outcomes a systematic review and meta-analysis of randomized controlled trials Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. The registrant confirms that the information supplied for this submission is accurate and complete. CRD bears no responsibility

2019 PROSPERO

62. Thyroid hypofunction and pregnancy outcomes

Thyroid hypofunction and pregnancy outcomes Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. The registrant confirms that the information supplied for this submission is accurate and complete. CRD bears no responsibility or liability for the content of this registration record, any associated files or external websites. Email salutation (e.g. "Dr Smith" or "Joanne

2019 PROSPERO

63. The effectiveness of thyroid hormone therapy in patients with subclinical hypothyroidism: a systematic review and meta-analysis

The effectiveness of thyroid hormone therapy in patients with subclinical hypothyroidism: a systematic review and meta-analysis Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. The registrant confirms that the information supplied for this submission is accurate and complete. CRD bears no responsibility or liability for the content of this registration record, any

2019 PROSPERO

64. The safety and efficacy of thermal ablation for primary papillary thyroid microcarcinoma:a meta-analysis

The safety and efficacy of thermal ablation for primary papillary thyroid microcarcinoma:a meta-analysis Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. The registrant confirms that the information supplied for this submission is accurate and complete. CRD bears no responsibility or liability for the content of this registration record, any associated files

2019 PROSPERO

65. The role of molecular genetics in the clinical management of sporadic medullary thyroid carcinoma: a systematic review

The role of molecular genetics in the clinical management of sporadic medullary thyroid carcinoma: a systematic review Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. The registrant confirms that the information supplied for this submission is accurate and complete. CRD bears no responsibility or liability for the content of this registration record, any

2019 PROSPERO

66. Comparisons between ultrasound-guided percutaneous thermal ablation and conventional thyroidectomy for benign thyroid nodules: a systematic review and meta-analysis

Comparisons between ultrasound-guided percutaneous thermal ablation and conventional thyroidectomy for benign thyroid nodules: a systematic review and meta-analysis Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. The registrant confirms that the information supplied for this submission is accurate and complete. CRD bears no responsibility or liability

2019 PROSPERO

67. Diagnostic performance of high sensitive basal serum thyroglobulin for detecting and predicting structural evidence of disease in differentiated thyroid cancer. A systematic review and meta-analysis

Diagnostic performance of high sensitive basal serum thyroglobulin for detecting and predicting structural evidence of disease in differentiated thyroid cancer. A systematic review and meta-analysis Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. The registrant confirms that the information supplied for this submission is accurate and complete. CRD bears

2019 PROSPERO

68. Association between thyroid dysfunction and risk of different cancer sites: a systematic review

Association between thyroid dysfunction and risk of different cancer sites: a systematic review Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. The registrant confirms that the information supplied for this submission is accurate and complete. CRD bears no responsibility or liability for the content of this registration record, any associated files or external

2019 PROSPERO

69. The influence of triclosan on the thyroid gland in humans and animals, a systematic review

The influence of triclosan on the thyroid gland in humans and animals, a systematic review Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. The registrant confirms that the information supplied for this submission is accurate and complete. CRD bears no responsibility or liability for the content of this registration record, any associated files or external websites

2019 PROSPERO

70. Safety and efficacy of peptide receptor radionuclide therapy in advanced differentiated and medullary thyroid carcinoma : a systematic review

Safety and efficacy of peptide receptor radionuclide therapy in advanced differentiated and medullary thyroid carcinoma : a systematic review Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. The registrant confirms that the information supplied for this submission is accurate and complete. CRD bears no responsibility or liability for the content

2019 PROSPERO

71. Morbidity outcomes of prophylactic central neck dissection with total thyroidectomy versus total thyroidectomy alone in patients with node-negative papillary thyroid cancer: a meta-analysis

Morbidity outcomes of prophylactic central neck dissection with total thyroidectomy versus total thyroidectomy alone in patients with node-negative papillary thyroid cancer: a meta-analysis Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. The registrant confirms that the information supplied for this submission is accurate and complete. CRD bears no responsibility

2019 PROSPERO

72. Impact of selective serotonin reuptake inhibitors in thyroid function among patients with major depressive disorder: a systematic review and meta-analysis

Impact of selective serotonin reuptake inhibitors in thyroid function among patients with major depressive disorder: a systematic review and meta-analysis Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. The registrant confirms that the information supplied for this submission is accurate and complete. CRD bears no responsibility or liability for the content

2019 PROSPERO

73. Imatinib associated with hepatic and thyroid toxicity: a systematic review

Imatinib associated with hepatic and thyroid toxicity: a systematic review Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. The registrant confirms that the information supplied for this submission is accurate and complete. CRD bears no responsibility or liability for the content of this registration record, any associated files or external websites. Email

2019 PROSPERO

74. Health-related quality of life in women with autoimmune thyroid disease during pregnancy and postpartum: systematic review and meta-analysis

Health-related quality of life in women with autoimmune thyroid disease during pregnancy and postpartum: systematic review and meta-analysis Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. The registrant confirms that the information supplied for this submission is accurate and complete. CRD bears no responsibility or liability for the content of this registration

2019 PROSPERO

75. Investigation on the correlation of PTCSC3 and its putative target genes with the risk of papillary thyroid carcinoma by meta-analyses

Investigation on the correlation of PTCSC3 and its putative target genes with the risk of papillary thyroid carcinoma by meta-analyses Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. The registrant confirms that the information supplied for this submission is accurate and complete. CRD bears no responsibility or liability for the content of this registration

2019 PROSPERO

76. A systematic review of protocols on the management of transient hypocalcaemia and hypoparathyroidism after thyroid surgery

A systematic review of protocols on the management of transient hypocalcaemia and hypoparathyroidism after thyroid surgery Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. The registrant confirms that the information supplied for this submission is accurate and complete. CRD bears no responsibility or liability for the content of this registration record, any

2019 PROSPERO

77. Predictive parameters of difficult intubation in thyroid surgery

Predictive parameters of difficult intubation in thyroid surgery Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. The registrant confirms that the information supplied for this submission is accurate and complete. CRD bears no responsibility or liability for the content of this registration record, any associated files or external websites. Email salutation (e.g

2019 PROSPERO

78. Thyroid Function Testing in the Diagnosis and Monitoring of Thyroid Function Disorder

Thyroid Function Testing in the Diagnosis and Monitoring of Thyroid Function Disorder Guidelines & Protocols Advisory Committee Thyroid Function Testing in the Diagnosis and Monitoring of Thyroid Function Disorder Effective Date: October 24, 2018 Scope This guideline outlines testing for thyroid dysfunction in patients (pediatric and adult), including pregnant women or women planning pregnancy, and the monitoring of patients treated for primary thyroid function disorders. It does not apply (...) to the BC Newborn Screening Program. This guideline outlines testing for thyroid stimulating hormone (TSH), free thyroxine (fT4), free triiodothyronine (fT3) and anti-thyroid peroxidase (TPO). Information on other tests, including thyroglobulin/antithyroglobulin (Tg/anti Tg) and antibodies to the thyroid stimulating hormone receptor (TRAb), are covered in the associated BC Guideline Hormone Testing – Indications and Appropriate Use. Key Recommendations • Routine thyroid function testing

2018 Clinical Practice Guidelines and Protocols in British Columbia

79. Vandetanib for treating medullary thyroid cancer

Vandetanib for treating medullary thyroid cancer V Vandetanib for treating medullary andetanib for treating medullary th thyroid cancer yroid cancer T echnology appraisal guidance Published: 12 December 2018 nice.org.uk/guidance/ta550 © NICE 2018. All rights reserved. Subject to Notice of rights (https://www.nice.org.uk/terms-and-conditions#notice-of- rights).Y Y our responsibility our responsibility The recommendations in this guidance represent the view of NICE, arrived at after careful (...) a responsibility to promote an environmentally sustainable health and care system and should assess and reduce the environmental impact of implementing NICE recommendations wherever possible. Vandetanib for treating medullary thyroid cancer (TA550) © NICE 2018. All rights reserved. Subject to Notice of rights (https://www.nice.org.uk/terms-and- conditions#notice-of-rights). Page 2 of 22Contents Contents 1 Recommendations 4 2 Information about vandetanib 5 3 Committee discussion 6 The condition and current

2018 National Institute for Health and Clinical Excellence - Technology Appraisals

80. Tocilizumab for thyroid eye disease. Full Text available with Trip Pro

Tocilizumab for thyroid eye disease. Thyroid eye disease (TED) is an autoimmune disorder that constitutes a major clinical and therapeutic challenge. Current treatment options for moderate-to-severe TED include immunotherapy, orbital radiotherapy and decompression surgery. Limited drugs of proven efficacy are available for the treatment of people with TED. Given the role in the pathogenesis of TED of interleukin (IL)-6 expression in adipocytes, fibroblasts and macrophages, the proposed theory

2018 Cochrane